Intraoperative Remifentanil Dose and Delayed Gastric Emptying after Pancreaticoduodenectomy: A Single-Centre Retrospective Cohort Study
This single-centre retrospective cohort study of 296 pancreaticoduodenectomy patients found that higher cumulative intraoperative remifentanil doses are significantly associated with an increased risk of severe delayed gastric emptying, though the observational nature of the findings precludes establishing causality.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Recovering from major abdominal surgery is a journey the body must take on its own, but the path is often blocked by a stubborn complication known as delayed gastric emptying. After a surgeon removes the head of the pancreas and part of the surrounding intestine—a complex operation called a pancreaticoduodenectomy—the stomach sometimes refuses to wake up and move food forward. This condition, which affects between fifteen and forty percent of patients, forces them to remain on a tube draining their stomach for weeks, delays their return to eating solid food, and keeps them in the hospital longer than necessary. While surgeons have long focused on the mechanics of the operation itself to prevent this issue, a quieter question has lingered in the operating room: could the medicines used to keep patients asleep and pain-free be part of the problem? Specifically, powerful painkillers known as opioids are known to slow down the natural muscle movements of the gut, but it has been unclear whether the amount given during the surgery directly influences how long the stomach stays paralyzed afterward.
Researchers at Peking University Cancer Hospital & Institute set out to investigate this possibility by looking back at the records of nearly three hundred patients who underwent this specific surgery over several years. They focused on a particular opioid called remifentanil, a drug favored for its ability to be turned on and off quickly, which is often assumed to leave the body without a trace once the surgery ends. The team divided the patients into three groups based on how much of this drug they received: a low dose of two milligrams or less, a medium dose between two and four milligrams, and a high dose of more than four milligrams. They then carefully re-examined the medical records to see who developed the most severe form of delayed gastric emptying, defined as needing a stomach tube for more than two weeks or being unable to eat solid food after three weeks.
The results revealed a clear pattern. Among the patients who received the lowest amount of the drug, about nine percent experienced this severe complication. In the group with medium doses, the rate rose to roughly twelve percent. However, in the group that received the highest doses, the rate jumped to more than thirty percent. This trend held true even after the researchers adjusted for other factors that could influence recovery, such as how long the surgery lasted, how much blood was lost, and the patient's overall health. The data suggested that for every step up in the dose level, the likelihood of the stomach failing to recover on time increased significantly. The researchers also looked at other potential complications, such as infections or leaks from the surgical connection, and found that these issues did not follow the same pattern, suggesting the effect was specific to the stomach's ability to move.
Despite these striking numbers, the study stops short of declaring a cause-and-effect relationship. Because this was an analysis of past records rather than a new experiment where doctors deliberately changed the drug amounts, it is possible that other unmeasured factors influenced the results. For instance, surgeons might have chosen to give more pain medication to patients who were already expected to have a more difficult or complex surgery, and that complexity itself could be the real reason for the delayed recovery. The authors emphasize that their findings are a strong signal that warrants further investigation, not a final verdict. They propose that the link between higher doses of this specific painkiller and a slower stomach recovery is real enough to be tested in future, controlled studies. Until such proof is available, the observation serves as a reminder that the choices made during anesthesia may have lasting consequences for how quickly a patient can return to normal life after one of the most demanding operations in surgery.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.